The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody.
 
Taiji Koyama
No Relationships to Disclose
 
Naomi Kiyota
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Eisai; Lilly Japan; Merck Serono; MSD; Ono Pharmaceutical
Consulting or Advisory Role - Adlai Nortye; Ono Pharmaceutical; Shift Zero
Research Funding - Adlai Nortye (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Ono Pharmaceutical (Inst); Rakuten Medical (Inst)
 
Yoshinori Imamura
Speakers' Bureau - Daiichi Sankyo/UCB Japan; MSD
 
Shogen Boku
Speakers' Bureau - Chugai Pharma; Daiichi Sankyo Co. Ltd.; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Daiichi Sankyo Co. Ltd. (Inst)
 
Nobuhiro Shibata
Consulting or Advisory Role - Kyowa Kirin Co., Ltd.
Speakers' Bureau - Becton Dickinson; Chugai Pharma; Daiichi Sankyo Co., Ltd.; Eisai; Kyowa Kirin Co., Ltd.; Merck; MSD K.K.; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Daiichi Sankyo Co., Ltd. (Inst); MSD K.K. (Inst); Ono Pharmaceutical (Inst)
 
Hironaga Satake
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Kaoru Tanaka
Honoraria - AstraZeneca; Bristol-Myers Squibb; Eisai; Kyowa Kirin Co., Ltd.; Merck Serono; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Hidetoshi Hayashi
Honoraria - Amgen; AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Guardant Health; Lilly; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Pfizer; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Janssen
Research Funding - Abbvie (Inst); AC Medical (Inst); Astellas Pharma (Inst); AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Associates Co., Ltd. (Inst); GlaxoSmithKline (Inst); Japan Clinical Research Operations (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical; Otsuka (Inst); PAREXEL (Inst); Pfizer (Inst); PPD-SNBL (Inst); Quintiles Inc. (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
Patents, Royalties, Other Intellectual Property - Sysmex
 
Shigemichi Iwae
Consulting or Advisory Role - Merck (Inst)
Speakers' Bureau - Bristol-Myers Squibb Japan; Merck; MSD; Ono Pharmaceutical
Research Funding - Ascent Development Services (Inst); GlaxoSmithKline (Inst); Merck (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Takuma Onoe
No Relationships to Disclose
 
Yukinori Asada
No Relationships to Disclose
 
Tomoko Yamazaki
Speakers' Bureau - Merck; MSD K.K; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Merck; MSD (Inst); Ono Pharmaceutical (Inst)
 
Taku Nose
No Relationships to Disclose
 
Shinya Ohata
No Relationships to Disclose
 
Shiro Kimbara
No Relationships to Disclose
 
Yoshiaki Nagatani
No Relationships to Disclose
 
Hironobu Minami
Honoraria - Abbvie; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Eisai; Kyowa Hakko Kirin; Lilly Japan; Nihon Servier; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Ono Pharmaceutical
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Mitsubishi Tanabe Pharma (Inst); MSD (Inst); Nihonkayaku (Inst); Nippon Shinyaku (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Teijin Pharma (Inst)